ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
64,081.27
1.90%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) Noticias

REPL Replimune Group Inc

6.95
0.39 (5.95%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Replimune Group Inc REPL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.39 5.95% 6.95 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
6.80 6.605 7.08 6.95 6.56
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/4/202416:00GLOBEInterim Results from the ARTACUS Clinical Trial of RP1..
04/4/202407:00GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
26/3/202406:30GLOBEReplimune Announces Appointment of Sushil Patel to CEO and..
06/3/202407:00GLOBEReplimune to Present at the American Association for Cancer..
05/3/202407:00GLOBEReplimune to Present at Three Upcoming Investor Conferences
14/2/202406:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202407:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/2/202407:05EDGAR2Form 8-K - Current report
08/2/202407:00GLOBEReplimune Reports Fiscal Third Quarter 2024 Financial..
16/1/202403:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
16/1/202402:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
08/1/202407:00EDGAR2Form 8-K - Current report
28/12/202307:00GLOBEReplimune to Present at the 42nd Annual J.P. Morgan..
26/12/202316:15EDGAR2Form 8-K - Current report
05/12/202306:19EDGAR2Form 8-K - Current report
05/12/202306:00GLOBEReplimune Shares Initial Primary Analysis Results from..
17/11/202319:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202319:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202308:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
07/11/202316:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202307:15EDGAR2Form 8-K - Current report
07/11/202307:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
03/11/202318:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
20/9/202319:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202319:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/9/202315:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
19/9/202307:15EDGAR2Form 8-K - Current report
19/9/202307:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
13/9/202320:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202308:17EDGAR2Form 8-K - Current report
24/8/202319:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202319:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202308:04EDGAR2Form 8-K - Current report
03/8/202307:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
03/8/202307:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202307:09EDGAR2Form 8-K - Current report
03/8/202307:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
01/8/202307:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
31/7/202315:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
26/7/202319:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/7/202316:08EDGAR2Form ARS - Annual Report to Security Holders
26/7/202316:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/7/202316:02EDGAR2Form DEF 14A - Other definitive proxy statements
20/7/202307:56EDGAR2Form 8-K - Current report
20/7/202307:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
11/7/202320:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202315:27EDGAR2Form 144 - Report of proposed sale of securities
06/6/202309:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
05/6/202307:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
03/6/202313:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..

Su Consulta Reciente

NASDAQ
REPL
Replimune
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados